Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment Article (Faculty180)

cited authors

  • Montgomery, Jazzmyne; Lybbert, Daniel; Sana, Sherjeel; El-Zawahry, Ahmed; Peabody, James; Pearce, Tiffany; Adams, Nicole; Deebajah, Mustafa; Dynda, Danuta; Babaian, Kara; Crabtree, Jane; Delfino, Kristin; McVary, Kevin; Robinson, Kathy; Rao, Krishna; Alanee, Shaheen

description

  • To report urinary bother, urinalysis changes, disease-free survival (DFS), and overall survival (OS) over 2 years for subjects enrolled in a phase I dose-escalation trial (NCT02324582) of intravesical Bacillus Calmette-Guérin (BCG) in combination with systemic pembrolizumab for recurrent or persistent high-grade non-muscle invasive bladder cancer (HGNMIBC).

authors

publication date

  • 2024

published in

start page

  • 102059

volume

  • 22